Philippe Genereux
Latest contributions
When the interventional cardiologist meets the surgeon
18 Nov 2025 – From PCR London Valves 2025
This session highlights collaborative approaches between interventional cardiologists and surgeons in complex valve interventions. It includes cases such as transfemoral valve-in-valve TAVI in bio-Bentall patients with chronic aortic dissection, critical decision-making in life-threatening scenarios, the importance of access choice in TMVR, mechanical leaflet modification of failed...
Pills and pumps: targeting heart failure before and after surgical and transcatheter valve interventions
18 Nov 2025 – From PCR London Valves 2025
This session examines the integrated role of heart failure therapies in the peri- and post-procedural management of patients undergoing surgical and transcatheter valve interventions. It reviews current and emerging clinical trial data, discusses identifying high-risk patients, and explores advanced modalities such as cardiac resynchronization and circulatory...
TAVI in 2025: transforming care with the new valvular heart disease guidelines
18 Nov 2025 – From PCR London Valves 2025
This session explores how the 2025 valvular heart disease guidelines are transforming the landscape of TAVI care and clinical decision-making. It highlights the paradigm shift in managing severe aortic stenosis and provides a global perspective on the challenges and strategies for managing an expanding TAVI patient...
PARTNER 3 — 7-year follow-up: what it means for low-risk patients
16 Nov 2025 – From PCR London Valves 2025
Philippe Généreux and Philippe Pibarot discuss the long-term findings from PARTNER 3 and their practical implications for patient care.
They review the 7-year comparison of transfemoral TAVR versus surgical aortic-valve replacement in symptomatic patients with severe aortic stenosis who are at low surgical risk, and why the...
From clinical benefits to cost effectiveness: impact of early intervention in asymptomatic severe AS
16 Nov 2025 – From PCR London Valves 2025
Francesco Saia discusses the clinical benefits of early intervention in asymptomatic severe aortic stenosis with Philippe Généreux and Tiffany Patterson. EARLY TAVR trial and supporting studies showed a reduction in death, stroke, and heart failure compared with surveillance. Economic modelling shows early intervention is cost-effective and...
Innovations in TAVR: clinical insights and future perspectives
16 Nov 2025 – From PCR London Valves 2025
Presenting featured research on TAVI, this session covers outcomes from centers without on-site cardiac surgery, comparative leaflet modification techniques, conscious sedation protocols, left ventricular health in timing TAVR, and long-term valve durability insights including seven-year follow-up data.
Hotline - TAVI - Part 1
16 Nov 2025 – From PCR London Valves 2025
This comprehensive session examines the latest evidence and clinical trial data on TAVI, including comparisons of balloon-expandable versus self-expanding valves in failed bioprostheses, techniques to reduce coronary obstruction risk, and real-world outcomes across diverse populations. Cost-effectiveness analyses and longitudinal studies further inform best practices for optimizing...
Beyond TAVI
16 Nov 2025 – From PCR London Valves 2025
This session offers a glimpse into cutting-edge structural heart interventions beyond TAVI. It introduces novel devices in early development stages targeting aortic valve stenosis and leaflet modification, discusses strategies to facilitate or defer TAVI, and provides opportunities for engagement with early-stage start-up partners innovating in structural...
Latest learnings on the treatment of asymptomatic severe aortic stenosis from the EARLY TAVR
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Christopher Cook, Philippe Genereux, and Victoria Delgado discuss key results from the EARLY TAVR study.
In asymptomatic patients with severe aortic stenosis, early intervention was associated with significantly less cardiac damage at 2 years, compared to a surveillance strategy that led to extensive damage...
TAVI and the left ventricular myocardium
23 May 2025 – From EuroPCR 2025
Understand the intricate relationship between TAVI and left ventricular myocardium through discussions on cardiac damage stages, functional remodeling, and pharmacological interventions post-TAVR. This session also reviews prophylactic ECMO support in high-risk patients, offering a comprehensive perspective on optimizing TAVI outcomes.
Hotline TAVI 3: Challenging anatomical and clinical scenarios
22 May 2025 – From EuroPCR 2025
This hotline session presents challenging anatomical and clinical scenarios in TAVI, including outcomes in bicuspid aortic valve patients, chronic aortic regurgigation, comparisons of surgical versus percutaneous approaches, and real-world data on valve performance and resource utilization.
Inludes:
- Five-year outcomes from the Evolut low risk TAVR bicuspid study
- Surgical versus...
Leaflet modification to prevent coronary obstruction during TAVI
22 May 2025 – From EuroPCR 2025
This session addresses advanced leaflet modification techniques to prevent coronary obstruction during TAVI. Learn from detailed cases involving valve-in-valve interventions, treatment of failed stentless valves, homograft management, and dedicated devices for leaflet modification prior to valve-in-valve and valve-in-valve-in-valve procedures.
Emerging indications for TAVI in 2025
22 May 2025 – From EuroPCR 2025
Prepare for emerging TAVI indications anticipated in 2025. This session reviews clinical cases including asymptomatic severe aortic stenosis, moderate aortic stenosis with heart failure, and severe aortic regurgitation. It discusses supporting evidence from clinical trials, evolving transcatheter technologies, and practical treatment approaches for these novel indications.
Hotline TAVI 1: extended analysis of the randomised trials
21 May 2025 – From EuroPCR 2025
Gain comprehensive insights from extended analyses of randomized TAVI trials. This session reviews five-year UK TAVI outcomes, cardiac damage evolution in asymptomatic aortic stenosis, one-year results from the LANDMARK trial, and three-year comparisons of balloon-expandable valves, highlighting critical clinical implications.
What are the emerging indications for TAVI in 2025?
22 May 2025 – From EuroPCR 2025
Tiffany Patterson, Nicolas Van Mieghem, and Philippe Généreux discuss emerging indications for TAVI in 2025. They review recent evidence on asymptomatic severe aortic stenosis, highlighting four randomised trials—RECOVERY, AVATAR, ONLY TAVR, and EVoLVeD—that show TAVI or surgical AVR reduces hospitalisations for heart failure and trends toward...
Early detection and treatment of aortic stenosis
25 Nov 2024 – From PCR London Valves 2024
Want to learn about the latest advancements in the early detection and treatment of aortic stenosis? Mayra Guerrero and Philippe Genereux discuss the benefits of early intervention (even in asymptomatic patients), the optimal timing for treatment and explore how artificial intelligence can enhance diagnosis, particularly in...
Mind the gap! - What's missing in the field of transcatheter aortic valve interventions
25 Nov 2024 – From PCR London Valves 2024
This session aims to uncover the hidden gaps in the field of transcatheter aortic valve interventions (TAVI). Explore strategies for optimizing hemodynamics, durability, flow, and frame expansion post-TAVI. Review current knowledge and emerging approaches to improve hemodynamic performance, device durability, and flow dynamics after TAVI. Discuss...
Early diagnosis and lifetime management of valvular heart disease: new tools and treatment paradigms
25 Nov 2024 – From PCR London Valves 2024
What if we could detect and treat progressive heart valve disease before it worsens? Dives into the latest breakthroughs with this video, showcasing how emerging technologies and innovative strategies are transforming patient outcomes.
Gain insights from the RECOVERY, AVATAR, EVOLVED and EARLY TAVR trials, and discover how AI,...
New frontiers in TAVI: have we reached them?
25 Nov 2024 – From PCR London Valves 2024
Discover the latest advancements in TAVI as we look into the results of the EARLY TAVR and RHEIA trials. Explore how these groundbreaking findings may influence clinical practice guidelines and shape the future of TAVI, as well as the remaining unmet clinical needs in TAVI.
Pre-emptive TAVI for asymptomatic severe aortic stenosis - From headlines to clinical practice
24 Nov 2024 – From PCR London Valves 2024
Is early TAVI the right choice for your asymptomatic patients with severe aortic stenosis? In this video, we break down the latest clinical trials, including EARLY TAVR and EVOLVED, to help you navigate the complex decision-making process.
Find out what these studies really tell us about the...
Focus on TAVI in female patients
25 Oct 2024
Didier Tchetche, Sabine Bleiziffer, Philippe Généreux, and Julia Mascherbauer explore the latest evidence about women and aortic stenosis.
Asymptomatic severe aortic stenosis: Will these trials change my practice?
16 May 2024 – From EuroPCR 2024
This session, in collaboration with Partners in Learning, explores the emerging evidence on the use of transcatheter aortic valve implantation (TAVI) in patients with asymptomatic severe aortic stenosis. It covers data from registries and randomized controlled trials, the current guideline recommendations, and the potential impact of...
TAVI Hotline: new devices, new approaches
15 May 2024 – From EuroPCR 2024
Valve-in-valve: utility of splitting devices
15 May 2024 – From EuroPCR 2024
This session focuses on the use of specialized splitting devices for transcatheter aortic valve-in-valve procedures. It features a case series demonstrating the application of a dedicated splitting device in failed TAVI valves, as well as the use of the BASILICA technique for transcatheter aortic valve replacement....
ShortCut leads the way for leaflet modification
14 May 2024 – From EuroPCR 2024
Check out this interview with Philippe Genereux, Danny Dvir and Susheel Kodali, where they discuss the ShortCut trial. Learn about the ShortCut device, the first tool for splitting leaflets in valve-in-valve procedures. Hear key insights, including the dual splitting technique, comparisons between BASILICA and ShortCut, and...
Challenging scenarios: bioprosthetic valve dysfunction
28 Nov 2022 – From PCR London Valves 2022
Consult this session to learn more about the different causes of bioprosthetic valve dysfunction and the best options (surgical, transcatheter or medical) for the management of patients with this kind of dysfunction, as well as to discover how valve design impacts on durability and what the future holds...
Rapid-fire abstracts: Session 5
28 Nov 2022 – From PCR London Valves 2022
Consult this session to discover a selection of abstracts presented during PCR LV 2022: impact of right ventricular dysfunction on the outcomes of TAVI - Insights from nationwide database, impact of COVID-19 pandemic on TAVI activity: a worldwide registry, redo isolated tricuspid valve surgery - Prediction of...
Hot TAVI topics - Emerging indications
27 Nov 2022 – From PCR London Valves 2022
Consult this session on hot TAVI topics to learn more about the under-treatment problem of patients with aortic valve disease, the rationale behind emerging TAVI indications and ongoing trials, as well as the nuances of patient selection and the key role of cardiac imaging in identifying markers of...
Therapy of valvular heart diseases: a patient-centred innovation journey
27 Nov 2022 – From PCR London Valves 2022
Join a team of experts as they review together the complete spectrum of valvular heart disease and ways in which we can manage it using emerging novel technologies.
Patient risk factors and outcome in contemporary TAVI
17 May 2022 – From EuroPCR 2022
Watch these videos to learn more about the patient's risk factors and outcome after TAVI in various situations: with atrial fibrillation and history of PCI, with Diabetes Mellitus, with aortic stenosis based on cardiac damage, and more!
